232 related articles for article (PubMed ID: 37237706)
1. A Systematic Review on Antimicrobial Pharmacokinetic Differences between Asian and Non-Asian Adult Populations.
Setiawan E; Cotta MO; Roberts JA; Abdul-Aziz MH
Antibiotics (Basel); 2023 Apr; 12(5):. PubMed ID: 37237706
[TBL] [Abstract][Full Text] [Related]
2. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.
Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2016 Nov; 48(5):542-546. PubMed ID: 27771187
[TBL] [Abstract][Full Text] [Related]
3. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review.
Alobaid AS; Hites M; Lipman J; Taccone FS; Roberts JA
Int J Antimicrob Agents; 2016 Apr; 47(4):259-68. PubMed ID: 26988339
[TBL] [Abstract][Full Text] [Related]
4. A UPLC-MS/MS method for simultaneous determination of eight special-grade antimicrobials in human plasma and application in TDM.
Qi Y; Liu G
J Pharm Biomed Anal; 2022 Oct; 220():114964. PubMed ID: 36084471
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
Novelli A; Adembri C; Livi P; Fallani S; Mazzei T; De Gaudio AR
Clin Pharmacokinet; 2005; 44(5):539-49. PubMed ID: 15871639
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.
Abdul-Aziz MH; Abd Rahman AN; Mat-Nor MB; Sulaiman H; Wallis SC; Lipman J; Roberts JA; Staatz CE
Antimicrob Agents Chemother; 2016 Jan; 60(1):206-14. PubMed ID: 26482304
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.
Nandy P; Samtani MN; Lin R
Antimicrob Agents Chemother; 2010 Jun; 54(6):2354-9. PubMed ID: 20385854
[TBL] [Abstract][Full Text] [Related]
9. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
10. Interethnic differences in pharmacokinetics of antibacterials.
Tsai D; Jamal JA; Davis JS; Lipman J; Roberts JA
Clin Pharmacokinet; 2015 Mar; 54(3):243-60. PubMed ID: 25385446
[TBL] [Abstract][Full Text] [Related]
11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
12. Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens.
Adiwidjaja J; Gross AS; Boddy AV; McLachlan AJ
Br J Clin Pharmacol; 2022 Feb; 88(4):1735-1750. PubMed ID: 34535920
[TBL] [Abstract][Full Text] [Related]
13. Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.
Natale S; Bradley J; Nguyen WH; Tran T; Ny P; La K; Vivian E; Le J
Pharmacotherapy; 2017 Mar; 37(3):361-378. PubMed ID: 28079262
[TBL] [Abstract][Full Text] [Related]
14. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Jamal JA; Udy AA; Lipman J; Roberts JA
Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics and Dose Optimization of Vancomycin in Critically Ill Children.
Sridharan K; Abbasi MY; Mulubwa M
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):539-546. PubMed ID: 34156647
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients.
Hahn J; Choi JH; Chang MJ
J Clin Pharm Ther; 2017 Dec; 42(6):661-671. PubMed ID: 28948652
[TBL] [Abstract][Full Text] [Related]
17. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
Lewis SJ; Kays MB; Mueller BA
J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
[TBL] [Abstract][Full Text] [Related]
19. Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy.
Li L; Li X; Xia Y; Chu Y; Zhong H; Li J; Liang P; Bu Y; Zhao R; Liao Y; Yang P; Lu X; Jiang S
Front Pharmacol; 2020; 11():786. PubMed ID: 32547394
[TBL] [Abstract][Full Text] [Related]
20. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
Goff DA; Nicolau DP
Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
